, AIDS by the numbers. AIDS_by_the_Numbers_2015_en.pdf, 2015.
, Annual Report, 2015.
Positive outcomes of HAART at 24 months in HIV-infected patients in Cambodia, AIDS, vol.21, pp.2293-301, 2007. ,
Response to highly active antiretroviral therapy among severely immunocompromised HIV-infected patients in Cambodia, AIDS, vol.21, pp.351-360, 2007. ,
Short communication: three years follow-up of first-line antiretroviral therapy in Cambodia: negative impact of prior antiretroviral treatment, AIDS Res Hum Retroviruses, vol.27, pp.597-603, 2011. ,
High survival and treatment success sustained after two and three years of first-line ART for children in Cambodia, J Int AIDS Soc, vol.13, p.11, 2010. ,
Simplified assessment of antiretroviral adherence and prediction of virological efficacy in HIV-infected patients in Cambodia, AIDS Res Treat, p.142076, 2010. ,
Adherence to antiretroviral therapy in patients enrolled in a comprehensive care program in Cambodia: a 24-month follow-up assessment, Antivir Ther, vol.13, pp.697-703, 2008. ,
URL : https://hal.archives-ouvertes.fr/inserm-00320461
High efficacy of lopinavir/r-based second-line antiretroviral treatment after 24 months of follow up at ESTHER/Calmette Hospital in Phnom Penh, Cambodia. J Int AIDS Soc, 2011. ,
URL : https://hal.archives-ouvertes.fr/pasteur-00598973
AIDS Working Group of MSF. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries, JAMA, vol.304, pp.303-315, 2010. ,
Secondline HIV therapy outcomes and determinants of mortality at the largest HIV referral center in Southern Vietnam, Medicine, vol.94, 2015. ,
Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database, J Acquir Immune Defic Syndr, vol.68, pp.186-95, 2015. ,
, Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, 2013.
The dynamic of adherence to highly active antiretroviral therapy: results from the French national APROCO cohort, J Acquir Immune Defic Syndr, vol.28, pp.232-241, 2001. ,
Virologic and immunologic outcomes of the second-line regimens of antiretroviral therapy among HIV-infected PATIENTS in Thailand, J Int Assoc Physicians AIDS Care (Chic), vol.10, pp.57-63, 2011. ,
Treatment outcomes of patients on second-line antiretroviral therapy in resource-limited settings: a systematic review and meta-analysis, AIDS, vol.26, pp.929-967, 2012. ,
Virological outcomes of second-line protease inhibitor-based treatment for human immunodeficiency virus type 1 in a high-prevalence rural South African setting: a competing-risks prospective cohort analysis, Clin Infect Dis, vol.64, pp.1006-1022, 2017. ,
Outcome of patients on second line antiretroviral therapy under programmatic condition in India, BMC Infect Dis, vol.15, p.517, 2015. ,
Intensive adherence counselling for HIV-infected individuals failing second-line antiretroviral therapy in, Trop Med Int Health, vol.21, issue.9, pp.1131-1138, 2016. ,
Adherence to PI-based 2nd-line regimens in Cambodia is not simply a question of individual behaviour: the ANRS 12276 2PICAM study, Trop Med Int Health, vol.22, issue.11, pp.1428-1463, 2017. ,
URL : https://hal.archives-ouvertes.fr/inserm-01985861
Persistence and adherence to single-tablet regimens in HIV treatment: a cohort study from the French national healthcare insurance database, J Antimicrob Chemother, vol.70, pp.2121-2129, 2015. ,
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE study, J Acquir Immune Defic Syndr, vol.53, pp.323-355, 2010. ,
Comparison of antiretroviral regimens: adverse effects and tolerability failure that cause regimen switching, vol.47, pp.231-239, 2015. ,
Accumulation of protease mutations among patients failing second-line antiretroviral therapy and response to salvage therapy in Nigeria, PLoS One, vol.8, 2013. ,
High prevalence of PI resistance in patients failing second-line ART in Vietnam, J Antimicrob Chemother, vol.71, pp.762-74, 2016. ,
Protease inhibitor resistance in the first 3 years of second-line antiretroviral therapy for HIV-1 in Sub-Saharan Africa, J Infect Dis, vol.214, issue.6, pp.873-83, 2016. ,
, Geneva: World Health Organization, 2017.
HIV-1 drug resistance mutations: potential applications for point-of-care genotypic resistance testing, PLoS One, vol.10, 2015. ,
Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study, Lancet HIV, vol.3, issue.16, p.30011, 2016. ,
Raltegravir non-inferior to nucleoside based regimens in second-line therapy with lopinavir/ritonavir over 96 weeks: a randomised open label study for the treatment of HIV-1 infection, PLoS One, vol.10, 2015. ,
Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART, J Antimicrob Chemother, vol.71, pp.1056-62, 2016. ,
Dolutegravirbased monotherapy or dual therapy maintains a high proportion of viral suppression even in highly experienced HIV-1-infected patients, J Antimicrob Chemother, vol.71, 2016. ,